ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election
of Directors; Appointment of Principal Officers.
Pharmaceuticals Inc. (Alexion) and a member of the Board of
Directors of Alexion (the Board), informed the Board that he will
not stand for reelection as a Board member and will retire as
Chairman of the Board and as a Director at the end of his term
effective as of the Annual Meeting of Shareholders scheduled for
May 10, 2017. Dr. Bell will continue to serve as Chairman of the
Board and as a director until his retirement. Dr. Bell’s
retirement was not the result of any disagreement with Alexion on
any matter relating to Alexion’s operations, policies or
practices.
entered into an amendment to their Letter Agreement, dated April 1,
2015 (the Amendment), which addresses the treatment of equity
awards held by Dr. Bell. The Amendment provides that Dr. Bells
equity awards will become immediately vested (to the extent earned,
in the case of any performance share units held by Dr. Bell) upon
his retirement and that he may continue to exercise his stock
option awards through their applicable expiration dates.
Amendment is filed as Exhibit 10.1 to this Current Report on Form
8-K and incorporated herein by reference.
retirement is filed as Exhibit 99.1 to this Current Report on Form
8-K.
|
10.1
|
Amendment to Letter Agreement, by and between Alexion
Pharmaceuticals, Inc. and Dr. Leonard Bell, dated March 2, 2017. |
|
99.1
|
Press Release issued by Alexion Pharmaceuticals, Inc. on
March 2, 2017 relating to the retirement of Dr. Bell. |
About ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders. ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) Recent Trading Information
ALEXION PHARMACEUTICALS, INC. (NASDAQ:ALXN) closed its last trading session down -1.27 at 132.94 with 1,244,475 shares trading hands.
